文献速递前列腺癌

PSMA PET在前列腺癌根治性治疗后生化复发中评估局部复发与远处转移的作用:系统综述与荟萃分析

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2025-05-19

该系统综述与荟萃分析纳入43项研究共8119例根治性治疗(RP或RT)后生化复发的前列腺癌患者,评估PSMA PET的诊断性能。PSMA PET阳性率异质性显著,RT后阳性率92%高于RP后60%,且随PSA升高而增加,从PSA 0.2-0.5 ng/ml的48%升至PSA>2 ng/ml的>90%;按解剖部位局部复发23%、盆腔淋巴结32%、骨转移16%、内脏转移仅1%。

要点

  • PSMA PET阳性率在RT后显著高于RP后(92% vs 60%,p<0.001)。
  • PSMA PET阳性率随PSA升高而增加,PSA 0.2-0.5 ng/ml为48%,PSA>2 ng/ml超过90%。
  • RP后生化复发患者即使PSA低至0.2-0.5 ng/ml,约半数PSMA PET有阳性发现。

核心结论

  • PSMA PET在生化复发患者中阳性率变异大,主要与治疗类型、PSA水平和解剖部位相关。
  • RP后生化复发患者即使低PSA(0.2-0.5 ng/ml)约半数PSMA PET阳性。
  • RT后PSMA PET使用多与Phoenix标准一致,多数研究在PSA≥2 ng/ml时进行。

研究设计与样本

  • 系统综述与荟萃分析,检索Web of Science/MEDLINE、Cochrane Library和EMBASE从建库至2024年4月25日。
  • 纳入43项回顾性或前瞻性研究,共8119例根治性治疗(RP或RT)后生化复发的前列腺癌患者。
  • 使用QUADAS-2工具评估偏倚风险,采用随机效应模型评估PSMA PET阳性率。

主要发现

  • PSMA PET阳性率研究间异质性显著(τ2=0.6;p<0.001),按PSA分层后部分缓解。
  • RT后阳性率92%显著高于RP后60%(p<0.001)。
  • 按解剖部位阳性率:局部复发23%,盆腔淋巴结32%,盆腔外淋巴结14%,骨转移16%,内脏转移1%。
  • PSA 0.2-0.5 ng/ml时阳性率48%,PSA>2 ng/ml时阳性率>90%。
  • RP时Gleason评分(GS)≤7与8-10的阳性率分别为50%和62%,差异无统计学意义(p=0.08)。

关键数值与推荐

  • PSMA PET阳性率:RT后92%,RP后60%(p<0.001)。
  • 按部位阳性率:局部复发23%,盆腔淋巴结32%,盆腔外淋巴结14%,骨转移16%,内脏转移1%。
  • 按PSA分层阳性率:0.2-0.5 ng/ml为48%,>2 ng/ml为>90%。
  • GS≤7阳性率50%,GS 8-10阳性率62%(p=0.08)。

临床怎么用

  • RP后生化复发患者即使PSA低至0.2-0.5 ng/ml,可考虑PSMA PET评估,约半数有阳性发现。
  • RT后生化复发患者PSMA PET使用多与Phoenix标准一致,多数研究在PSA≥2 ng/ml时进行。
  • PSMA PET结果有助于指导挽救性治疗决策,但需结合治疗类型、PSA和怀疑部位解读。

局限性

  • 研究间异质性显著,限制了结果的普遍性。
  • 异质性主要与治疗类型、PSA水平和解剖部位差异相关。
  • 需进一步研究优化PSMA PET的PSA阈值,尤其是RT后设置。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) radioligands has an established role in the assessment of recurrence of prostate cancer (PC) after primary treatment. However, an updated understanding of its diagnostic utility is warranted, particularly in the context of emerging targeted and systemic treatment options for recurrent PC. Our aim was to evaluate the diagnostic performance of PSMA PET for staging and detection of local or metastatic disease in patients with biochemical recurrence (BCR) following definitive treatment for PC. METHODS: We conducted a systematic review (Web of Science/MEDLINE, Cochrane Library, and EMBASE from inception to April 25, 2024) and meta-analysis. Eligible retrospective and prospective studies had extractable data on PSMA PET for patients with BCR after radical prostatectomy (RP) or radiation therapy (RT). Risk of bias was assessed using the QUADAS-2 tool. Random-effects models were used to evaluate PSMA PET positivity rates across clinical subgroups stratified by PSA, primary treatment, PSMA PET radioligand, and anatomic lesion sites. KEY FINDINGS AND LIMITATIONS: A total of 43 studies (8119 patients) were included. PSMA PET positivity rates varied substantially among patients with BCR after primary definitive treatment, with significant study heterogeneity (τ2 = 0.6; p < 0.001), which was mitigated in part after stratification by PSA category. Positivity rates were significantly higher after RT (92%) than after RP (60%; p < 0.001). PSMA PET positivity by anatomic location was 23% for local recurrence, 32% for pelvic nodes, 14% for extrapelvic nodes, 16% for bone metastases, and just 1% for visceral metastases. The positivity rate increased with PSA, from 48% at PSA 0.2-0.5 ng/ml to >90% at PSA >2 ng/ml. Gleason score (GS) at RP did not significantly influence the positivity rate (50% for GS ≤7 vs 62% for GS 8-10; p = 0.08). Heterogeneity limits the generalisability of our findings. CONCLUSIONS AND CLINICAL IMPLICATIONS: We observed substantial variability in PSMA PET positivity rates in BCR because of significant study heterogeneity, mostly related to differences in treatment type, PSA, and anatomic sites. In post-RP BCR, approximately half of patients undergoing PSMA PET had positive findings, even at low PSA (0.2-0.5 ng/ml). In the post-RT setting, PSMA PET use was generally aligned with the Phoenix criterion for BCR, with most studies performing PSMA PET at PSA ≥2 ng/ml. Further research is needed to refine PSA thresholds for PSMA PET, particularly in the post-RT setting, and to assess its role in guiding salvage treatment decisions.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Mazzone E, Thomson A, Chen DC, et al. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis. Eur Urol. 2025. PMID: 40393864. doi:10.1016/j.eururo.2025.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。